Latest Intelligence on Immunology and Inflammation

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Pfizer: Bextra blues

Data presented at a recent American Heart Association meeting suggests that Pfizer's [PFE] COX-2 drug, Bextra, approved for arthritis pain, may have worse cardiovascular effects than Merck & Co's [MRK] recently withdrawn Vioxx. Having already been denied an indication for migraine and with the prospect of a black box warning, Bextra could now be in deep trouble.

Published By Datamonitor
12 Nov 2004
CommentWire
CommentWire

Pfizer/Pharmacia: study erodes Celebrex's advantages

Published By Datamonitor
22 Aug 2001
Expert View
Expert View

Pfizer/Pharmacia: laying down a challenge to fellow big pharmas

The proposed merger between Pfizer and Pharmacia will consolidate Pfizer's position as the dominant force in the pharma industry. The sheer magnitude of the combined company threatens to overwhelm many competitors unless they too pair up - for rivals such as GlaxoSmithKline, Aventis, AstraZeneca, Merck and Bristol-Myers Squibb, it may be time to follow suit.

Published By Datamonitor
19 Jul 2002
CommentWire
CommentWire

Pfizer/Pharmacia: approval expected right on time

Pfizer's intention to acquire Pharmacia for $57 billion is expected to gain US FTC and EU MTF approval by the end of Q1 despite "open issues". The acquisition will firm up Pfizer's position as the top pharmaceutical company in the world, giving it direct control over 10 of world's best selling drugs, including blockbuster arthritis drugs Celebrex and Bextra.

Published By Datamonitor
31 Jan 2003
CommentWire
CommentWire

Pfizer/Merck: another boost to Celebrex

A study has found that Pfizer's Celebrex has a higher safety level than Merck & Co's rival COX-2 inhibitor Vioxx. While the difference is small, it could prove significant: there is little else to differentiate the two drugs. Celebrex is already the market leader, largely due to Pfizer's marketing strength; this result will surely boost solidify its hold on the arthritis market.

Published By Datamonitor
04 Oct 2002
Expert View
Expert View

Pfizer's tasocitinib poised to make its mark in psoriasis

On October 7, 2010, Pfizer presented positive late-stage psoriasis trial data for oral tasocitinib at the annual European Academy of Dermatology and Venereology meeting in Gothenburg. The treatment has now progressed to Phase III trials in psoriasis, and as a first-in-class drug for the indication, Datamonitor believes it will have a distinct advantage, although pricing will be key for uptake.

Published By Datamonitor
11 Oct 2010
Expert View
Expert View

Pfizer's novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug's analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, Datamonitor expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy.

Published By Datamonitor
08 Feb 2010
Expert View
Expert View

Pandemic threat reignites influenza vaccine market

The last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin business with high barriers to entry. The flu vaccines market has been at the forefront of this trend, partially fuelled by fear of an impending pandemic. This trend is set to continue, although flu vaccine revenues will depend on ambitious coverage targets being met.

Published By Datamonitor
20 Apr 2006
Expert View
Expert View

Osteoporosis: compliance is the key

Drugs already available to treat osteoporosis are known to reduce the risk of bone fractures by around 50%. However a new report has revealed that the osteoporosis development pipeline features a raft of newer drugs that are likely to offer only incremental improvements on this level of effectiveness - a finding that raises a number of questions.

Published By Datamonitor
25 Nov 2005
CommentWire
CommentWire

Osteoarthritis: work and chopsticks identified as risk factors

Researchers in the US and China have found that even light repetitive movements, such as typing or using chopsticks, may increase the risk of osteoarthritis and other musculoskeletal diseases. Experts have been divided over whether repetitive tasks like typing can cause musculoskeletal damage, but this evidence suggests that daily tasks do indeed pose a risk.

Published By Datamonitor
14 Nov 2003

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.